Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Complementing MAbs

Biothera thinks its Imprime PGG beta-glucan, a soluble carbohydrate, could be combined with complement-fixing MAbs to improve their efficacy compared to the MAbs alone in some cancers.

Last week, the company's scientists published preclinical data

Read the full 345 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers